ライフサイエンスコーパス: IFN-beta

1 IFN-beta and other IFN-related and neuroinflammatory gen

2 IFN-beta did not induce inflammatory cytokine production

3 IFN-beta essentially modulates the host response against

4 IFN-beta induction did not require live bacteria (i.e.,

5 IFN-beta is a key component of the innate immune respons

6 IFN-beta pretreatment was more effective in protecting a

7 IFN-beta significantly inhibited VZV replication in both

8 IFN-beta treatment of primary astrocytes resulted in bot

9 ety of fingolimod versus interferon beta-1a (IFN beta-1a) in paediatric-onset multiple sclerosis (PoM

10 e contained higher levels of CCL2, IL-1beta, IFN-beta, and MIF in their alveolar lining fluid.

11 SAP reduced serum levels of IL-23, IFN-beta, MCP-1, and tumor necrosis factor-alpha, wherea

12 ling and the subsequent transcription of 309 IFN-beta-stimulated genes in a dose-dependent way.

13 [IFN]-beta-1a intramuscularly [IM], n = 38; IFN-beta-1a subcutaneously [SC], n = 68; IFN-beta-1b SC,

14 38; IFN-beta-1a subcutaneously [SC], n = 68; IFN-beta-1b SC, n = 41; rituximab, n = 31; tocilizumab,

15 urified malaria pigment with DNase abrogated IFN-beta induction.

16 fragment (residues 1 to 349) could activate IFN-beta transcription more robustly than full-length NE

17 STING such as 2',3'-cGAMP and also activated IFN-beta and ISG expression; and (v) UL46 binds to both

18 dition to its well-known signaling activity, IFN-beta may be directly antimicrobial and be part of a

19 ng MSD.Measurements and Main Results: Adding IFN-beta to MDMs, alveolar macrophages, and PBECs prior

20 ith influenza virus either prior to or after IFN-beta stimulation.

21 n virus induction of interferon (IFN)-alpha, IFN-beta and IFN-lambda in bronchial epithelial and bron

22 Here we show that in addition to IFN-alpha, IFN-beta and IL-27 also affect Vpu-mediated BST-2 downre

23 Type I interferons (IFNs) (IFN-alpha, IFN-beta) and type III IFNs (IFN-lambda) share many prop

24 was used to detect expression of IFN-alpha, IFN-beta, and the PRRs: Toll-like receptor 3, melanoma d

25 leukin-6 (IL-6) mRNAs, as well as IFN-alpha, IFN-beta, and TNF-alpha mRNA levels induced by Sendai vi

26 ga1b1-Foxo3a-/- mice show reduced IFN-alpha, IFN-beta, IFN-lambda2/3 in response to challenge with RV

27 Network analyses identified IFN-alpha, IFN-beta, IL-1RI and TNF-alpha as combined biomarkers th

28 ion of Klebsiella hemolysin gene; TNF-alpha; IFN-beta; nucleotide-binding domain, leucine-rich-contai

29 Here, we experimentally evolved an IFN-beta-hypersensitive CA mutant which showed decreased

30 ogical importance of IFN-Is, discovery of an IFN-beta-inducing microbial molecule represents a potent

31 a gene expression, and in the presence of an IFN-beta-mediated antiviral state, ExoN(-) viral RNA lev

32 ent-derived TNBC tumors demonstrates that an IFN-beta metagene signature correlates with improved pat

33 sults in the activation of astrocytes via an IFN-beta-mediated process and that these astrocytes late

34 t [IFN-beta-KO] mice or mice treated with an IFN-beta-blocking antibody) or IFN-alpha (IFN regulatory

35 s, 107 each were treated with fingolimod and IFN beta-1a for up to 2 years.

36 of IL-1beta, whereas production of IL-10 and IFN-beta is reduced.

37 a, interferon (IFN) regulatory factor 3, and IFN-beta levels than BCG-wild type (WT) in vitro in muri

38 , CCL20, C-X-C chemokine ligand 8, IL-6, and IFN-beta.

39 acrophages have increased Akt activation and IFN-beta production but defects in ERK1/2 and STAT3 acti

40 earch is in demonstrating that IFN-alpha and IFN-beta both have protective roles during acute chikung

41 TLR4 activation, prevention of TNF-alpha and IFN-beta production, and parasite survival.

42 he type I interferon receptor (IFN-alpha and IFN-beta receptor subunit 1 [IFNAR1]), T cells, and B ce

43 Prolonged IFN-alpha and IFN-beta responses can lead to harmful proinflammatory e

44 Type I (IFN-alpha and IFN-beta) and III (IFN-lambda) interferons are host-prod

45 evels of expression of type I (IFN-alpha and IFN-beta) and type III (IFN-lambda1 to IFNlambda3) IFNs

46 to understand how type I IFNs (IFN-alpha and IFN-beta) might act directly on nociceptors in the dorsa

47 Along with IFN-alpha and IFN-beta, IFN-gamma was demonstrated to control filoviru

48 lls ectopically expressing bat IFN-alpha and IFN-beta.

49 Interferon alpha (IFN-alpha) and IFN-beta are type I IFNs that are induced by virus infec

50 (IFNs), including alpha IFN (IFN-alpha) and IFN-beta, potently suppress HIV-1 replication by upregul

51 Type 1 IFNs, including the IFN-alphas and IFN-beta, activate the interferon-alpha/beta receptor (I

52 arly viral replication and dissemination and IFN-beta modulating neutrophil-mediated inflammation.IMP

53 whereas the shared response to IFN-gamma and IFN-beta in neutrophils was increased.

54 genes were upregulated by both IFN-gamma and IFN-beta.

55 Using IFNAR1 and IFN-beta variants, we show that this interface contribut

56 ession of IFN regulatory factor 7 (IRF7) and IFN-beta, as well as increased nuclear exclusion of FOXO

57 ession pathways of TNF-alpha, NF-kappaB, and IFN-beta.

58 In summary, association of STING and IFN-beta signaling pathways with Brucella-induced UPR un

59 on, cytosolic nucleic acid transfection, and IFN-beta treatment.

60 1 signaling, IRF3 nuclear translocation, and IFN-beta production.

61 ivate primary astrocytes was blocked by anti-IFN-beta antibodies.

62 tact, despite beta-arrestin 2 activation, as IFN-beta, IFN-gamma, IFN-lambda1, IRF7, TRAIL, and MxA e

63 several type I IFN-associated genes, such as IFN-beta and guanylate-binding proteins (GBPs), are down

64 ked to type I IFN signaling pathway, such as IFN-beta, IFN regulatory factor 1, and guanylate-binding

65 wn host factor-independent pathways to avoid IFN-beta-mediated restriction by altering capsid sequenc

66 wn host factor-independent pathways to avoid IFN-beta-mediated restriction.

67 CHIKV pathogenesis in mice lacking IFN-beta (IFN-beta knockout [IFN-beta-KO] mice or mice treated wit

68 Treatment with IFN-beta (IFN-beta) led to a less aggressive epithelial/non-CSC-li

69 which induce genes encoding interferon beta (IFN-beta) and other immune mediators.

70 ntagonizes the induction of interferon beta (IFN-beta) by interacting with and degrading retinoic aci

71 cellular pretreatment with interferon beta (IFN-beta) in a dose-dependent manner.

72 sensitive to inhibition by interferon beta (IFN-beta) in vitro and functions as a highly efficacious

73 -like protease, antagonizes interferon beta (IFN-beta) production by cleaving the NF-kappaB essential

74 s-induced activation of the interferon beta (IFN-beta) promoter and interferon regulatory factor 3 (I

75 nificantly higher levels of interferon beta (IFN-beta) than the polymerase complexes of the 2016-17 o

76 ation biomarkers, including interferon beta (IFN-beta), interleukin-6 (IL-6), interleukin-6 receptor

77 in cells prestimulated with interferon beta (IFN-beta), we identified a small number of factors requi

78 us-infected neurons produce interferon beta (IFN-beta).

79 we found that the cytokine interferon-beta (IFN-beta) can induce miR-1 expression in mammalian cells

80 tration of acetate mediated interferon-beta (IFN-beta) response by increasing expression of interfero

81 ng type II IFN-gamma signaling, also blocked IFN-beta responses by inhibiting STAT1/STAT2-mediated tr

82 eplication is significantly less affected by IFN-beta in PML(-/-) cells than in parental PML(+/+) cel

83 bial peptides was killed more efficiently by IFN-beta than was the wild-type S. aureus, and immunoblo

84 gamma production, which could be provided by IFN-beta or IL-12.

85 Here we show that BST-2 upregulation by IFN-beta and interleukin-27 (IL-27) also increases the s

86 bdomain-3 that is differentially utilized by IFN-beta and IFN-alpha for signal transduction.

87 nzae was significantly impaired by poly I:C, IFN-beta, and IFN-gamma in COPD cells.

88 d mice expressed higher mRNA levels of CCL2, IFN-beta, IL-10, IL-12p40, TNF-alpha, and MIF than young

89 merged from this adaptation indeed conferred IFN-beta resistance.

90 In contrast, IFN-beta-KO mice displayed minimal differences in viral

91 r mRNA levels of immune-regulatory cytokines IFN-beta and IL-10.

92 of house dust mite-sensitized mice to dampen IFN-beta expression and prevent the T(H)1-promoting dend

93 Sendai virus infection efficiency, decreased IFN-beta, IFN-lambda1, and interferon-stimulated chemoki

94 pact model in adult male IFN-beta-deficient (IFN-beta(-/-)) mice and assessed post-traumatic neuroinf

95 nally, we report that RIPK1 kinase-dependent IFN-beta production may be elicited in an analogous fash

96 membrane potential regulates STING-dependent IFN-beta induction independently of ATP synthesis.

97 Notably, GBS induced a TLR7-dependent IFN-beta signal only in MPhi-like but not in DC-like cel

98 gregates facilitate canonical TRIF-dependent IFN-beta production downstream of the LPS receptor TLR4.

99 s and pathologic tissue injury, in directing IFN-beta production in macrophages.

100 how that catalytic activity of RIPK1 directs IFN-beta synthesis induced by LPS in mice.

101 that the dominant signaling cascade driving IFN-beta in macrophages (MPhi) in streptococcal infectio

102 s inhibits osteoclastogenesis via endogenous IFN-beta-mediated feedback inhibition.

103 pression patterns associated with endogenous IFN-beta.

104 ce, an effect that was reversed by exogenous IFN-beta administration, and Ifnar1(-/-) mice had reduce

105 ease of HRV, which is prevented by exogenous IFN-beta treatment.

106 augmentation of these responses by exogenous IFN-beta, but not IFN-lambda, protected MCs against HRV

107 lular growth was fully restored by exogenous IFN-beta.

108 ations.Objectives: The dynamics of exogenous IFN-beta activity were investigated to inform on future

109 intermittent prophylactic doses of exogenous IFN-beta to modulate viral infection.

110 Ifnar1(-/-)) and administration of exogenous IFN-beta were used to study the functional role of type-

111 f cytolytic toxins), which are essential for IFN-beta induction via cGAS-STING.

112 that mAb blockade revealed a unique role for IFN-beta in Lyme arthritis development in B6.C3-Bbaa1 mi

113 we report a positive translational role for IFN-beta, as gene expression profiling of patient-derive

114 However, ExoN(-) virus generated from IFN-beta-pretreated cells had reduced specific infectivi

115 at, in addition to known cytokine functions, IFN-beta is antimicrobial.

116 Furthermore, IFN-beta is also important for the UPR induction during

117 ils in response to stimulation by IFN-gamma, IFN-beta, IFN-lambda, IL-4, IL-13, and IL-10 cytokines t

118 in contrast, Armenia/07 infection generated IFN-beta levels below those of uninfected cells.

119 d STAT5 phosphorylation downstream of RIG-I, IFN-beta, and IL-4, but not GM-CSF, signaling.

120 d STAT5 phosphorylation downstream of RIG-I, IFN-beta, and interleukin-4 (IL-4), but not granulocyte-

121 In summary, we identify IFN-beta formation as part of the antistreptococcal repe

122 pression, and type I IFN by measuring IFNB1 (IFN-beta) and CXCL10 expression in human cell lines and

123 genes and secreted IFNs of types I and III (IFN-beta and IFN-lambda).

124 l-based assays to investigate this important IFN-beta binding interface that is centered on IFNAR1 re

125 howed decreased binding to CPSF6 and CypA in IFN-beta-treated cells.

126 itive function impairments were decreased in IFN-beta(-/-) TBI mice compared with their injured WT co

127 of WT mice, whereas levels were mitigated in IFN-beta(-/-) mice.

128 volume and hippocampal neurodegeneration in IFN-beta(-/-) mice.

129 tal tissues, and depletion of neutrophils in IFN-beta-KO but not IRF7-KO mice mitigated musculoskelet

130 ExoN(-) virus replication did not result in IFN-beta gene expression, and in the presence of an IFN-

131 l capsid, we adapted the RGDA/Q112D virus in IFN-beta-treated cells.

132 ns respond by producing cytokines, including IFN-beta.

133 duces target genes in macrophages, including IFN-beta.

134 and suggest that, in its absence, increased IFN-beta signaling may result in increased neuroinflamma

135 cytogenes infection as a result of increased IFN-beta-mediated apoptosis of major leukocyte cell popu

136 Indeed, IFN-beta shows a synergistic effect in inducing the IRE1

137 utilizes the host NE-TLR machinery to induce IFN-beta necessary for parasite survival and growth duri

138 ng from EAV or PRRSV nsp4 scission to induce IFN-beta production, we serendipitously found that a NEM

139 the resulting proteins are unable to induce IFN-beta, are intrinsically less stable than wild-type I

140 urine VSV infection model, commensal-induced IFN-beta regulated natural resistance to virus infection

141 s identified as a regulator of RIG-I-induced IFN-beta production.

142 es whose products affected viral RNA-induced IFN-beta production and highlighted the complexity of th

143 d that EAV nsp4 also inhibited virus-induced IFN-beta production by targeting NEMO for proteolytic cl

144 MLAV VP40 also inhibited virus-induced IFN-beta promoter activation, a property shared by MARV

145 y which a specific commensal microbe induces IFN-beta was identified.

146 8 and TIR domain-containing adapter-inducing IFN-beta, thereby dampening the activation of NF-kappaB

147 oll/IL-1R domain-containing adaptor inducing IFN-beta-dependent pathways.

148 oll/IL-1R domain-containing adaptor inducing IFN-beta/ TNFR-associated factor 3 pathway was highly up

149 nce [TIR] domain-containing adaptor-inducing IFN-beta (TRIF), in the control of NiV infection in mice

150 To date, studies of inhaled IFN-beta treatment have not demonstrated a significant e

151 Instead, MSK1 and -2 inhibit IFN-beta expression via the induction of dual-specificit

152 teria colonization in the airways, inhibited IFN-beta and in the absence of Staphylococcus (S.) aureu

153 more relevant production of beta interferon (IFN-beta) and IFN-lambda1 in response to baculovirus inf

154 sphorylation and downstream beta interferon (IFN-beta) gene transcription.

155 e or paracrine signaling by beta interferon (IFN-beta) is essential for many of the responses of macr

156 pe, T953, downregulates the beta interferon (IFN-beta) response in vitro in equine endothelial cells

157 se to this, a high level of beta interferon (IFN-beta) was produced during NH/P68 infection; in contr

158 activity cannot counteract beta interferon (IFN-beta)-induced restriction of viral infection, are hi

159 golimod (n=107) or once-weekly intramuscular IFN beta-1a (n=108) in this flexible duration study.

160 ts with moderate or severe ARDS, intravenous IFN-beta-1a administered for 6 days, compared with place

161 eveal antiviral effects of acetate involving IFN-beta in lung epithelial cells and engagement of GPR4

162 cies (ROS) levels are elevated, mTOR and IRF/IFN-beta signaling pathways are enhanced, leading to cel

163 We successfully isolated IFN-beta-resistant viruses which contained either a sing

164 in mice lacking IFN-beta (IFN-beta knockout [IFN-beta-KO] mice or mice treated with an IFN-beta-block

165 evaluated CHIKV pathogenesis in mice lacking IFN-beta (IFN-beta knockout [IFN-beta-KO] mice or mice t

166 Mice lacking IFN-beta had increased neutrophil infiltration into musc

167 -) macrophages displayed significantly lower IFN-beta mRNA than background mice macrophages, and the

168 ntrolled cortical impact model in adult male IFN-beta-deficient (IFN-beta(-/-)) mice and assessed pos

169 Twice as many IFN beta-1a-treated than fingolimod-treated patients had

170 ZBP1-mediated cell death via the RIG-I-MAVS-IFN-beta signaling axis.

171 lly expressed, ORF8b inhibited IRF3-mediated IFN-beta expression induced by Sendai virus and poly(I:C

172 nic:polycytidylic acid (poly I:C) 30 mug/ml, IFN-beta 10 mug/ml, IFN-gamma 10 mug/ml, or medium contr

173 the mechanisms by which C3a and C5a modulate IFN-beta expression during L. monocytogenes infection we

174 ssed higher levels of IFI16 and induced more IFN-beta upon HSV-2 infection.

175 HP1 and HeLa cells causes significantly more IFN-beta production in response to cytosolic nucleic aci

176 ich induced a decrease in IFN-alpha, but not IFN-beta expression.

177 uenzae was also impaired by poly I:C but not IFN-beta or IFN-gamma in COPD MDM.

178 Blockade of IFN-alpha but not IFN-beta signaling using either an antibody or a selecti

179 ucing ISG transcription, IFN-lambda (but not IFN-beta) specifically activated a translation-independe

180 DA/Q112D virus in the presence or absence of IFN-beta, whereas the G94D/G116R mutations affected reve

181 contributes significantly to the affinity of IFN-beta for IFNAR1, its ability to activate STAT1, the

182 eading to the production of large amounts of IFN-beta.

183 s of type I IFNs have led to the approval of IFN-beta for the treatment of relapsing-remitting MS.

184 omains and residues enabling complexation of IFN-beta to IFNAR1.

185 Genetic control of IFN-beta expression was also identified in bone marrow-d

186 Enhancement of IFN-beta induction in cells infected with ORF8b-deficien

187 t is associated with increased expression of IFN-beta and other IFN-related genes.

188 RelA deficiency abrogated the expression of IFN-beta in response to virus infections.

189 monstrate here that macrophage expression of IFN-beta is negatively regulated by mitogen- and stress-

190 We report that B cell expression of IFN-beta is required for optimal survival and TLR7 respo

191 se data suggest that T1 B cell expression of IFN-beta plays a key role in regulating responsiveness t

192 popolysaccharide (LPS)-induced expression of IFN-beta was elevated in both MSK1/2 knockout mice and m

193 infection of LAD2 MCs induced expression of IFN-beta, IFN-lambda and IFN-stimulated genes.

194 Here we investigate the expression of IFN-beta, IFN-lambda1 (IL-29), IFN-lambda2/3 (IL-28A/B)

195 We observed increased expression of IFN-beta, IFN-lambda1/IL-29, OAS and viperin in asthmati

196 ls, RelA typically induces the expression of IFN-beta, which restrains viral propagation in neighbori

197 he Bacteroidetes phylum induce expression of IFN-beta.

198 he C and N termini of the B and C helices of IFN-beta, respectively.

199 late the IFN-I response through induction of IFN-beta by colonic DCs.

200 stimulation of TLR4, the rapid induction of IFN-beta was inhibited in cells loaded with oxLDL, where

201 eak may be related to the lower induction of IFN-beta.

202 nstrated to be dependent on the induction of IFN-beta.

203 ing is insufficient to explain inhibition of IFN-beta promoter activation.

204 Inhibition of IFN-beta reduces post-traumatic neuroinflammation and ne

205 Inhibition of IFN-beta signaling resulted in reduced neuroinflammation

206 of genetic or pharmacological inhibition of IFN-beta, a key component of type I IFN mechanisms to ad

207 The interaction of IFN-beta with its receptor IFNAR1 (interferon alpha/beta

208 he 2014-15 outbreak induced higher levels of IFN-beta despite relatively minor differences in replica

209 high SASSAD scores with the lowest levels of IFN-beta, IL-1, and epithelial cytokines.

210 rase complexes also induced higher levels of IFN-beta.

211 31461630

212 eceive an intravenous injection of 10 mug of IFN-beta-1a (144 patients) or placebo (152 patients) onc

213 Overexpression of IFN-beta in the CNS of adult wild-type mice, but not of

214 transcription factors, and overexpression of IFN-beta mRNA and protein were similar in MSK1/2 and DUS

215 philic, asthmatics display overexpression of IFN-beta, IFN-lambda1/IL-29 and ISGs in their sputum cel

216 sms were implicated in the overexpression of IFN-beta: first, JNK-mediated activation of c-jun, which

217 To determine whether specific parts of IFN-beta are antimicrobial, we synthesized IFN-beta heli

218 everse transcription only in the presence of IFN-beta, most consistent with a mechanism of the disrup

219 A/DI RNA-expression stimulated production of IFN-beta and IFN-lambda1 and conditioned media from thes

220 RIPK1 and RIPK3 kinases in the production of IFN-beta during the host inflammatory responses to bacte

221 IFN, illustrating that de novo production of IFN-beta in response to VSV plays a key role in antivira

222 i-viral and anti-proliferative properties of IFN-beta.

223 fection lasted for 24 hours after removal of IFN-beta and was maintained albeit reduced up to 1 week

224 Here, we investigated the role of IFN-beta in secondary injury after TBI using a controlle

225 expression of HSP70 relieved suppression of IFN-beta expression by ORF8b in an IKKepsilon-dependent

226 IPK1 and RIPK3 kinase-dependent synthesis of IFN-beta is markedly induced by avirulent strains of Gra

227 ent Armenia/07 virus blocks the synthesis of IFN-beta, a key mediator between the innate and adaptive

228 population displayed robust transcription of IFN-beta mRNA, and this did not appear to depend on vira

229 aid the future design of clinical trials of IFN-beta in asthma and COPD.

230 These results do not support the use of IFN-beta-1a in the management of ARDS.

231 Mice lacking either IFN-alpha or IFN-beta developed severe clinical disease following inf

232 cells, the mNLS variant reduced TNF-alpha or IFN-beta mRNA expression to a similar extent as did WT S

233 IL-13 and monocyte responses to IFN-gamma or IFN-beta emerged as opposing predictors of patient survi

234 ated genes (ISGs) following WNV infection or IFN-beta treatment.

235 -hypersensitive virus can evolve to overcome IFN-beta-mediated blocks targeting the viral capsid, we

236 ge cells and subsequently stimulate a potent IFN-beta response in recipient cells via activation of e

237 r cells accumulate cytosolic DNA and produce IFN-beta in a cGAS-STING-dependent manner, which renders

238 RIG-I pathway signaling and thereby promotes IFN-beta induction and the antiviral response.

239 ontribute to the ability of MSKs to regulate IFN-beta expression.

240 ing AMPK activity also failed to up-regulate IFN-beta and TNF-alpha after treatment with DMXAA or the

241 n patients presenting with an FCDE, early sc IFN beta-1a tiw administration versus DT prolonged time

242 ntense lesion volume change was lower for sc IFN beta-1a tiw versus DT (nominal p<0.01).

243 ensION): patients initially randomised to sc IFN beta-1a and not reaching clinically definite MS (cli

244 nd T1 hypointense lesions were lower with sc IFN beta-1a qw (nominal p<0.05) and tiw versus DT (nomin

245 Serum IFN-beta levels from PP2ACalpha-knockout mice treated wi

246 icant contributor to the expression of serum IFN-beta, whereas MyD88 was not.

247 bacterial and fungal beta-glucans stimulate IFN-beta production by dendritic cells (DCs) following d

248 Moreover, C5a and C3a suppress IFN-beta production by acting through their respective r

249 C5a and C3a suppress IFN-beta production in a manner that is dependent on Bru

250 rt in this article that C5a and C3a suppress IFN-beta production in response to L. monocytogenes via

251 g through their specific receptors, suppress IFN-beta expression by modulation of a distinct innate c

252 ouse embryonic fibroblasts (MEFs) suppressed IFN-beta and TNF-alpha induction following stimulation w

253 f IFN-beta are antimicrobial, we synthesized IFN-beta helix 4 and found that it is sufficient to perm

254 In this report, we demonstrate that IFN-beta-1a was highly effective in inhibiting in vitro

255 ociated polysaccharide A, we determined that IFN-beta expression was induced via TLR4-TRIF signaling.

256 antimicrobial peptides, and we observed that IFN-beta can directly kill Staphylococcus aureus Further

257 In this article, we report that IFN-beta signaling in murine bone marrow-derived macroph

258 pe S. aureus, and immunoblotting showed that IFN-beta interacts with the bacterial cell surface.

259 These preclinical findings suggest that IFN-beta may be a potential therapeutic target for TBI.

260 These results suggest that IFN-beta, likely released from reovirus-infected neurons

261 partially due to accelerated atrophy in the IFN beta-1a group.

262 t difference in 28-day mortality between the IFN-beta-1a vs placebo groups (26.4% vs 23.0%; differenc

263 EMO cleavage products were abrogated for the IFN-beta-inducing capacity.

264 during the study (41 patients [28.5%] in the IFN-beta-1a group and 33 [21.7%] in the placebo group).

265 days (interquartile range, -1 to 20) in the IFN-beta-1a group and 8.5 days (interquartile range, 0 t

266 Parts of the IFN-beta molecular surface (especially helix 4) are cati

267 ignificantly inhibited the activation of the IFN-beta promoter after Sendai virus infection or poly(I

268 NS1 also suppressed the activation of the IFN-beta promoter when it was stimulated by interferon r

269 Guided by the crystal structure of the IFN-beta-IFNAR1 complex, we used truncation variants and

270 ood profiles from tuberculosis patients, the IFN-beta-specific neutrophil signature was reduced in tu

271 aprolin, which we show is able to target the IFN-beta mRNA.

272 ated activation of c-jun, which binds to the IFN-beta promoter, and second, p38-mediated inactivation

273 g complex, the key residues underpinning the IFN-beta-IFNAR1 interaction are unknown.

274 icity and promoted antiviral effects through IFN-beta response.

275 Thus, IFN-beta may be a potential therapeutic target for TBI.S

276 sensitivity of parental SP100(+/+) cells to IFN-beta and support replication of the DeltaICP0 virus.

277 In contrast to IFN-beta, GBS induced TNF-alpha independently of TLR7.

278 ND10 structures increase in cells exposed to IFN-beta.

279 imited contribution of known host factors to IFN-beta resistance.

280 , in which heightened IRF3 activity leads to IFN-beta-induced disease.

281 ment, and myostatin expression was linked to IFN-beta production.

282 ession increases RIG-I-mediated signaling to IFN-beta and that RAB1B deletion reduces signaling of th

283 We identified transcripts specific to IFN-beta stimulation, whereas other IFN signature genes

284 These two IFN-beta resistance mutations variably changed the sensi

285 Thr(78), Val(81), and Arg(82) that underlie IFN-beta-IFNAR1-mediated signaling and biological proces

286 m of the disruption of binding to an unknown IFN-beta-regulated host factor.

287 ation and activation of STAT1 and STAT2 upon IFN-beta stimulation.

288 CUA lesions per scan (60.7%, p<0.001) versus IFN beta-1a at EOS.

289 onsistent control of disease activity versus IFN beta-1a (including treatment-naive and younger patie

290 , p=0.014) were lower with fingolimod versus IFN beta-1a, the latter partially due to accelerated atr

291 I activity and ARBA for up to 2 years versus IFN beta-1a in PoMS.

292 AS-STING-IRF3 route in ASFV infection, where IFN-beta production or inhibition was found after infect

293 CHIKV replication and dissemination, whereas IFN-beta protects from CHIKV pathogenesis by limiting in

294 murine and human macrophages activated with IFN-beta.

295 In addition, priming cells with IFN-beta favors B. abortus survival in macrophages.

296 l-OTUD3 levels are inversely correlated with IFN-beta expression in influenza patients.

297 idues Tyr(240) and Tyr(274) interacting with IFN-beta residues Phe(63), Leu(64), Glu(77), Thr(78), Va

298 plicities of infection (MOI) without or with IFN-beta or IFN-lambda.

299 Treatment with IFN-beta (IFN-beta) led to a less aggressive epithelial/

300 gh levels of U-ISGF3 and that treatment with IFN-beta reduces CSC properties, suggesting a therapeuti